Genetron Holdings Ltd Stock Price, News & Analysis

Genetron Holdings Limited (Nasdaq: GTH) has announced an expanded partnership with the Wuxi municipal government in China for its HCCscreen^TM, a blood-based early screening test for hepatocellular carcinoma (HCC). Under a new joint venture, Genetron will own 90% and administer 150,000 tests over three years. This initiative aims to enhance liver cancer screening awareness and offers substantial supportive measures from Wuxi. Preliminary data indicate HCCscreen^TM achieves over 92% sensitivity, marking a significant step in cancer detection advancements in China.

Genetron Holdings Limited (NASDAQ: GTH) emphasizes the critical need for early disease detection, particularly cancer, as shared by CEO Sizhen Wang during a panel at the CNBC East Tech West Conference in Guangzhou, China. He highlighted that cancer leads global mortality rates, and early detection can significantly enhance patient outcomes. The company is advancing its early screening technology with innovations like the Mutation Capsule and the FDA-designated HCCscreen test for hepatocellular carcinoma. Genetron's comprehensive oncology portfolio aims to improve cancer management through ongoing monitoring and treatment recommendations.

Genetron Health (NASDAQ: GTH), a leading precision oncology platform in China, announced its participation in the CNBC East Tech West Conference in Guangzhou on Nov. 17-18, 2020. CEO Sizhen Wang will join a panel titled, “Innovative Ways in Tackling Life Threatening Disease,” on Nov. 18 at 9:30 am Beijing Time. The company focuses on molecular profiling tests and cancer screening products, aiming to revolutionize cancer treatment through advanced technologies. More information is available at their investor relations site.

Genetron Holdings Limited (NASDAQ:GTH) reported a 37.6% year-over-year revenue increase, reaching RMB112.0 million for Q3 2020. Diagnosis and monitoring revenue surged by 45.0% to RMB101.5 million. Gross margin improved to 62.2%, up from 44.2% a year ago. The company received FDA breakthrough device designation for its HCCscreen™ test. Although operating expenses rose by 7.4%, the operating loss decreased by 29.5% to RMB59.2 million. The cash position remains strong at RMB1,868.5 million. Guidance highlights continued growth in IVD and early screening sales.

Genetron Holdings Limited (Nasdaq: GTH), a leading precision oncology platform in China, announced its participation in six upcoming investor conferences. Key events include the China Renaissance Healthcare Summit on October 30 and the CICC Investment Forum on November 12. Genetron focuses on cancer molecular profiling, early screening, and diagnostic development. The company's comprehensive oncology solutions address needs from early detection to continuous monitoring. For more details, visit their investor relations page.

Genetron Holdings Limited (NASDAQ:GTH), a leading precision oncology platform in China, will report its third-quarter financial results for the period ending September 30, 2020, on November 9, 2020, before the US market opens. A conference call for investors is scheduled for 8:30 a.m. ET on the same day. Investors are encouraged to join the call 15 minutes early due to expected high volumes. Genetron specializes in molecular profiling tests and cancer screening, aiming to enhance cancer care through advanced technologies.

Genetron Holdings (Nasdaq: GTH) announced a collaboration with Hangzhou ImmuQuad Biotechnologies to develop Seq-MRD, a diagnostic assay for monitoring minimal residual disease in hematologic cancers. Genetron gains exclusive rights to research and commercialize Seq-MRD, while ImmuQuad will receive royalties. Additionally, Genetron made a minority equity investment in ImmuQuad. The Seq-MRD tool shows promise over traditional methods, aiming to enhance monitoring for various cancers within a significant market in China, where around 135,000 new cases of lymphoid malignancies were reported in 2017.

Genetron Holdings Limited (Nasdaq: GTH) announced that its blood-based NGS test, HCCscreen™, has received Breakthrough Device designation from the FDA for early detection of hepatocellular carcinoma (HCC) in high-risk individuals. This designation enables faster development and review processes, as well as potential Medicare coverage upon approval. Initial clinical data show HCCscreen™ has over 92% sensitivity and 93% specificity, outperforming standard care methods. The company aims to commercialize HCCscreen™ in the US and has plans to build a lab in Maryland for development and certification.